Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry

Citation

Gibson, P, Reddel, H, McDonald, V et al 2016, 'Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry', Internal Medicine Journal, vol. 46, no. 9, pp. 1054-1062.

Year

2016

Fields of Research

  • Respiratory Diseases
  • Allergy

Updated:  29 February 2024 / Responsible Officer:  Director (Research Services Division) / Page Contact:  Researchers